Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Danni Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang U…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Cyclin-Dependent Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
The dual degradation of cyclin-dependent kinases 12 and 13 (CDK12/13) is a promising therapeutic strategy for triple-negative breast cancer (TNBC), yet identifying clinical candidates with optimized pharmacological profiles remains an ongoing priority. Herein, we describe a rational, structure-based campaign to develop a highly potent and selective degrader. Systematic modification of an initial lead, which showed undesired off-target activity, led to the discovery of DN1679. This degrader potently and selectively removes CDK12/13 (DC50 < 10 nM) and shows a favorable therapeutic window, with high potency against TNBC cells but significantly reduced activity in nonmalignant cell lines. DN1679 possesses promising oral pharmacokinetic properties and, as a monotherapy, effectively suppresses tumor growth in a TNBC xenograft model. Notably, DN1679 demonstrates robust synergy with the PARP inhibitor olaparib in vivo, leading to significantly enhanced antitumor efficacy. The optimized pharmacological profile of DN1679 and its demonstrated synergistic activity establish it as a compelling therapeutic candidate for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China.
- Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China.
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou 310018, P. R. China.
- School of Medicine, Hangzhou City University, Hangzhou 310015, P. R. China.
ORCID-Profile: Cheng-Liang Zhu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Chen, D., Hu, J., Yu, Y., Li, K., Wang, T., Wang, Z., Yuan, Y., Shao, X., Ying, M., Yang, B., He, Q., Cao, J., Jiang, L., & Zhu, C. L. (2026). Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02232
Vancouver
Chen D, Hu J, Yu Y, Li K, Wang T, Wang Z, et al. Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02232
BibTeX
@article{Chen2026,
author = {Chen, Danni and Hu, Jiawen and Yu, Yiling and Li, Kailin and Wang, Tingting and Wang, Zidong and Yuan, Yi and Shao, Xuejing and Ying, Meidan and Yang, Bo and He, Qiaojun and Cao, Ji and Jiang, Li and Zhu, Cheng-Liang},
title = {Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02232}
}
EUVIMED